Use and limitations of varicella-zoster virus-specific serological testing to evaluate breakthrough disease in vaccinees and to screen for susceptibility to varicella

Journal of Infectious Diseases

Volumn 197, Issue SUPPL. 2, 2008, Pages

  Breuer, Judith ^a   Schmid, D Scott ^b   Gershon, Anne A ^c,d  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c New York Presbyterian Columbia University Medical Center   (United States)

^d BB 4 427 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; VIRUS ANTIBODY; VIRUS GLYCOPROTEIN;

ANTIBODY BLOOD LEVEL; ANTIBODY SCREENING; CELLULAR IMMUNITY; CHICKENPOX; CONFERENCE PAPER; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; IMMUNOASSAY; INFECTION SENSITIVITY; PRIORITY JOURNAL; SEROLOGY; VACCINATION; VACCINE FAILURE; VARICELLA ZOSTER VIRUS; VIRUS IMMUNITY;

ANTIBODIES, VIRAL; CHICKENPOX; CHICKENPOX VACCINE; HERPESVIRUS 3, HUMAN; HUMANS; SEROLOGIC TESTS;

EID: 42549085693     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/529448     Document Type: Conference Paper

References (46)

1. Gershon A, Chen J, LaRussa P, Steinberg S. Varicella-zoster virus. In: Murray PR, ed. Manual of clinical microbiology. Washington, DC: ASM Press [in press].
2. Saiman L, LaRussa P, Steinberg SP, et al. Persistence of immunity to varicella-zoster virus after vaccination of healthcare workers. Infect Control Hosp Epidemiol 2001; 22:279-83.
3. Williams V, Gershon A, Brunell PA. Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence. J Infect Dis 1974; 130:669-72.
4. Zaia JA, Oxman MN. Antibody to varicella-zoster virus-induced membrane antigen: immunofluorescence assay using monodisperse glutaraldehyde-fixed target cells. J Infect Dis 1977; 136:519-30.
5. Iltis JP, Castellano GA, Gerber P, Le C, Vujcic LK, Quinnan GV Jr. Comparison of the Raji cell line fluorescent antibody to membrane antigen test and the enzyme-linked immunosorbent assay for determination of immunity to varicella-zoster virus. J Clin Microbiol 1982; 16:878-84.
6. Grose C, Edmond BJ, Brunell PA. Complement-enhanced neutralizing antibody response to varicella-zoster virus. J Infect Dis 1979; 139:432-7.
7. Gershon AA, Larussa P, Steinberg S. Detection of antibodies to varicella-zoster virus using a latex agglutination assay. Clin Diagn Virol 1994; 2:271-7.
8. Steinberg SP, Gershon AA. Measurement of antibodies to varicella-zoster virus by using a latex agglutination test. J Clin Microbiol 1991;29:1527- 9.
9. Gershon AA, Steinberg SP, LaRussa P, Ferrara A, Hammerschlag M, Gelb L. Immunization of healthy adults with live attenuated varicella vaccine. J Infect Dis 1988; 158:132-7.
10. Gershon AA, Steinberg S, Gelb L, NIAID Collaborative Varicella Vaccine Study Group. Live attenuated varicella vaccine: efficacy for children with leukemia in remission. JAMA 1984; 252:355-62.
11. Landry ML, Ferguson D. Comparison of latex agglutination test with enzyme-linked immunosorbent assay for detection of antibody to varicella-zoster virus. J Clin Microbiol 1993; 31:3031-3.
12. Unadkat P, Newman B, Tedder RS. The detection of varicella zoster antibodies by simultaneous competitive EIA and its comparison with radioimmunoassay, latex agglutination and antiglobulin type EIA. J Virol Methods 1995; 51:145-52.
13. Behrman A, Schmid DS, Crivaro A, Watson B. A cluster of primary varicella cases among healthcare workers with false-positive varicella zoster virus titers. Infect Control Hosp Epidemiol 2003; 24:202-6.
14. Martins TB, Jaskowski TD, Schroder C, Streeter B, Hill HR. Comparison of three commercially available assays for detection of varicella-zoster virus antibody. Clin Diagn Lab Immunol 1994; 1:186-8.
15. Shigeta S, Baba M, Ogata M, Iijima S, Murai C. Anticomplement immunofluorescence for the titration of antibody to varicella-zoster virus. Microbiol Immunol 1981; 25:295-303.
16. Preissner CM, Steinberg SP, Gershon AA, Smith TF. Evaluation of the anticomplement immunofluorescence test for detection of antibody to varicella-zoster virus. J Clin Microbiol 1982; 16:373-6.
17. Landry ML, Cohen SD, Mayo DR, Fong CK, Andiman WA. Comparison of fluorescent-antibody-to-membrane-antigen test, indirect immunofluorescence assay, and a commercial enzyme-linked immunosorbent assay for determination of antibody to varicella-zoster virus. J Clin Microbiol 1987; 25:832-5.
18. Gallo D, Schmidt NJ. Comparison of anticomplement immunofluorescence and fluorescent antibody-to-membrane antigen tests for determination of immunity status to varicella-zoster virus and for serodifferentiation of varicella-zoster and herpes simplex virus infections. J Clin Microbiol 1981; 14:539-43.
19. Cremer NE, Cossen CK, Shell G, Diggs J, Gallo D, Schmidt N. Enzyme immunoassay versus plaque neutralization and other methods for determination of immune status to measles and varicella-zoster viruses and versus complement fixation for serodiagnosis of infections with those viruses. J Clin Microbiol 1985; 21:869-74.
20. Larussa P, Steinberg S, Waithe E, Hanna B, Holzman R. Comparison of five assays for antibody to varicella-zoster virus and the fluorescent-antibody-to- membrane-antigen test. J Clin Microbiol 1987; 25:2059-62.
21. Sauerbrei A, Farber I, Brandstadt A, Schacke M, Wutzler P. Immunofluorescence test for sensitive detection of varicella-zoster virus-specific IgG: an alternative to fluorescent antibody to membrane antigen test. J Virol Methods 2004; 119:25-30.
22. de Ory F, Echevarría JM, Kafatos G, et al. European seroepidemiology networks 2: standardization of assays for seroepidemiology of varicella zoster virus. J Clin Virol 2006; 36:111-8.
23. Wasmuth EH, Miller WJ. Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen. J Med Virol 1990; 32:189-93.
24. Maple PA, Gray J, Breuer J, Kafatos G, Parker S, Brown D. Performance of a time-resolved fluorescence immunoassay for measuring varicella-zoster virus immunoglobulin G levels in adults and comparison with commercial enzyme immunoassays and Merck glycoprotein enzyme immunoassay. Clin Vaccine Immunol 2006; 13:214-8.
25. Sauerbrei A, Wutzler P. Serological detection of varicella-zoster virus-specific immunoglobulin G by an enzyme-linked immunosorbent assay using glycoprotein antigen. J Clin Microbiol 2006; 44:3094-7.
26. Gershon AA, Steinberg SP, Gelb L. Clinical reinfection with varicella-zoster virus. J Infect Dis 1984; 149:137-42.
27. LaRussa P, Steinberg SP, Seeman MD, Gershon AA. Determination of immunity to varicella-zoster virus by means of an intradermal skin test. J Infect Dis 1985; 152:869-75.
28. Junker AK, Angus E, Thomas EE. Recurrent varicella-zoster virus infections in apparently immunocompetent children. Pediatr Infect Dis J 1991; 10:569-75.
29. LaRussa PS, Gershon AA, Steinberg SP, Chartrand SA. Antibodies to varicella-zoster virus glycoproteins I, II, and III in leukemic and healthy children. J Infect Dis 1990; 162:627-33.
30. Haumont M, Jurdan M, Kangro H, et al. Neutralizing antibody responses induced by varicella-zoster virus gE and gB glycoproteins following infection, reactivation or immunization. J Med Virol 1997; 53:63-8.
31. Johnson C, Rome LP, Stancin T, Kumar ML. Humoral immunity and clinical reinfections following varicella vaccine in healthy children. Pediatrics 1989; 84:418-21.
32. Gershon AA, Steinberg SP. Live attenuated varicella vaccine: protection in healthy adults compared with leukemic children. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. J Infect Dis 1990; 161:661-6.
33. Watson BM, Piercy SA, Plotkin SA, Starr SE. Modified chickenpox in children immunized with the Oka/Merck varicella vaccine. Pediatrics 1993; 91:17-22.
34. Asano Y, Suga S, Yoshikawa T, et al. Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 1994; 94:524-6.
35. Asano Y. Varicella vaccine: the Japanese experience. J Infect Dis 1996; 174(Suppl 3):S310-3.
36. Asano Y, Nagaie T, Miyata T, et al. Long-term protective immunity of recipients of the Oka strain of live varicella vaccine. Pediatrics 1985; 75:667-71.
37. Johnson C Stancin T, Fattlar Drome LP, Kumar ML. A long-term prospective study of varicella vaccine in healthy children. Pediatrics 1997; 100:761-6.
38. Gershon AA, Krugman S. Seroepidemiological survey of varicella: value of specific immunofluorescent antibody test. Pediatrics 1975; 56:1005-8.
39. Williams V, Gershon AA, Brunell P. Serologic response to varicella-zoster membrane antigens measured by indirect immunofluorescence. J Infect Dis 1974; 130:669-72.
40. Krah DL, Cho I, Schofield T, Ellis RW. Comparison of gpELISA and neutralizing antibody responses to Oka/Merck live varicella vaccine (Varivax) in children and adults. Vaccine 1997; 15:61-4.
41. Li S, Chan IS, Matthews H, et al. Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr Infect Dis J 2002; 21:337-42.
42. White CJ, Kuter BJ, Ngai A, et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J 1992; 11:19-23.
43. Kuter BJ, Weibel RE, Guess HA, et al. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 1991; 9:643-7.
44. Watson B, Gupta R, Randall T, Starr S. Persistence of cell-mediated and humoral immune responses in healthy children immunized with live attenuated varicella vaccine. J Infect Dis 1994; 169:197-9.
45. Watson B, Boardman C, Laufer D, et al. Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. Clin Infect Dis 1995; 20:316-9.
46. Clements DA, Armstrong CB, Ursano AM, Moggio MM, Walter EB, Wilfert CM. Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents. Pediatr Infect Dis J 1995; 14:874-9.